Monoclonal antibody desensitization in a patient with a generalized urticarial reaction following denosumab administration.
Denosumab is a human monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women with a high risk of fractures. To our knowledge, no cases of desensitization to this drug have been described in the literature. We report the first case of generalized urticarial reaction and facial angioedema after therapy with denosumab. A subcutaneous desensitization protocol was successfully completed in this patient. Rapid desensitization is a promising method for the delivery of denosumab after a hypersensitivity reaction, and should be considered in osteoporosis treatment when no acceptable therapeutic alternatives are available.
Pneumology-Allergy Department, Puerta del Mar University Hospital, Cádiz, Spain.
D
D
Gutiérrez-Fernández
Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron, 119, 08035 Barcelona, Spain.
María-Jesús
MJ
Cruz
Joaquín Pece Primary Care Centre, San Fernando, Cádiz Spain.
A
A
Foncubierta-Fernández
Allergy Department, Hospital Nuestra Señora del Prado, Talavera de la Reina, Toledo Spain.
A
A
Moreno-Ancillo
Hospital Pharmacy, Puerta del Mar University Hospital, Cádiz, Spain.
M J
MJ
Fernández-Anguita
Unidad de Gestión Clínica Aparato Locomotor, Rheumatology Department, Puerta del Mar University Hospital, Cádiz, Spain.
F
F
Medina-Varo
Unidad de Gestión Clínica Aparato Locomotor, Orthopaedic Surgery and Traumatology Department, Puerta del Mar University Hospital, Cádiz, Spain.
J A
JA
Andres-García
Hypersensitivity reaction; Osteoporosis; mABs